Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.24.3
Revenue Recognition (Tables)
9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Service Line
Revenue by Service Line
Three Months Ended September 30,
(in thousands) 2024 2023
Biologics and drug delivery
Disposable products $ 2,062  $ 455 
Services and license fees 2,369  3,032 
Subtotal – Biologics and drug delivery revenue 4,431  3,487 
Neurosurgery navigation and therapy
Disposable products 2,860  1,874 
Services —  44 
Subtotal – Neurosurgery navigation and therapy
2,860  1,918 
Capital equipment and software
Systems and software products 552  81 
Services 279  276 
Subtotal – Capital equipment and software revenue 831  357 
Total revenue $ 8,122  $ 5,762 
Nine Months Ended September 30,
(in thousands)
2024
2023
Biologics and drug delivery
Disposable products $ 4,286  $ 1,395 
Services and license fees 8,779  8,136 
Subtotal – Biologics and drug delivery revenue 13,065  9,531 
Neurosurgery navigation and therapy
Disposable products 7,373  5,550 
Services —  930 
Subtotal – Neurosurgery navigation and therapy
7,373  6,480 
Capital equipment and software
Systems and software products 2,394  432 
Services 787  702 
Subtotal – Capital equipment and software revenue 3,181  1,134 
Total revenue $ 23,619  $ 17,145 
Schedule of Other Current Assets
September 30, 2024
December 31, 2023
(in thousands)
Accounts receivable, net $ 3,875  $ 3,211 
Other contract assets
Unbilled receivables $ 662  $ 733 
Schedule of Revenue Recognized by Contract Liability The unearned portion of all such fees is classified as deferred revenue.
September 30, 2024
December 31, 2023
(in thousands)
Deferred revenues $ 1,732  $ 3,154